Companies
Flagship Pioneering
originates biotech platforms from scratch rather than investing in outside pitches — in April 2026 it launched Serif Biomedicines with an initial $50 million commitment to develop "Modified DNA" as a programmable, redosable therapeutic class, following its earlier origination of Moderna and, in 2024, Abiologics.
- Country
- United States
venture-creation
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Venture studios & biotech incubators | finance-investment | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.